Federal Cannabis Legality Remains Unresolved Despite State Progress

Federal Schedule I Status Unchanged

Cannabis remains a Schedule I controlled substance under federal law, the most restrictive classification reserved for drugs with no accepted medical use. The Drug Enforcement Administration hasn't rescheduled cannabis despite multiple petitions and ongoing administrative review processes. This classification puts cannabis in the same legal category as heroin and LSD under the Controlled Substances Act.

State-Level Legalization Creates Patchwork

Thirty-eight states have enacted medical or adult-use cannabis programs, but these laws don't override federal prohibition. State-licensed dispensaries, cultivators, and processors operate in direct violation of federal statutes. They're protected only by DOJ enforcement discretion policies that can change with each administration.

The conflict means:

• Interstate transport remains a federal felony
• Federal employees and contractors face termination for state-legal use
• National parks and federal buildings enforce zero-tolerance policies
• Immigration applicants can be denied for cannabis-related conduct

Banking Access Blocked by Federal Status

Most banks refuse cannabis accounts because federal money-laundering statutes treat state-legal revenue as proceeds of drug trafficking. The SAFE Banking Act has passed the House seven times since 2019. Never cleared the Senate. Operators rely on state-chartered credit unions, cash management services, and workarounds that increase security risks and operational costs.

280E Tax Penalty Costs Operators Millions

IRS Code Section 280E prohibits businesses trafficking in Schedule I substances from deducting ordinary expenses, resulting in effective tax rates exceeding 70 percent. State-legal cannabis companies can deduct only cost of goods sold. Payroll, rent, marketing, and compliance costs are non-deductible. This structural disadvantage has driven dozens of MSOs into distress or bankruptcy since 2024.

Rescheduling Debate Stalled in DEA Review

The DEA's review of a Health and Human Services recommendation to move cannabis to Schedule III has been pending since August 2023 with no resolution timeline. Schedule III would preserve federal prohibition but eliminate the 280E tax penalty and potentially open pathways to FDA-approved medications. The simplest explanation for the delay? Political risk. Neither party wants to own the decision in an election cycle.

Rescheduling to Schedule III wouldn't legalize cannabis for recreational use but would fundamentally change the economics for state-licensed operators by restoring normal tax deductions.

Congressional Gridlock Blocks Federal Reform

Comprehensive legalization bills including the MORE Act and CAOA have failed to advance beyond committee votes despite bipartisan public support exceeding 68 percent. Republican opposition centers on workplace safety and youth access concerns. Democratic sponsors have been unable to secure the 60 Senate votes needed to overcome a filibuster. For full background on this story, see the CannIntel topic hub on Federal Cannabis Legality.

What to Watch

The next catalyst is the DEA's final rule on rescheduling, expected no earlier than Q4 2026. Until then, state-legal operators face the same federal risks they've managed since Colorado and Washington launched adult-use sales in 2014. The patchwork will persist. Congress must act or the DEA must move. Neither is imminent.